ArticleJGH open : an open access journal of gastroenterology and hepatology2026
The Proctitis Paradox: Refractory Ulcerative Proctitis Associated With Development of Disease Complications in a Multicenter South Australian Cohort.
Article in JGH open : an open access journal of gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite limited extent, patients with ulcerative proctitis (UP) can suffer from debilitating symptoms, complications, and risk of disease extension. The aim was to provide a contemporary real-world insight into the management and outcomes of UP. Methods: A retrospective cohort study was conducted of UP patients attending three tertiary hospitals in Adelaide, South Australia, between 2015 and 2024. Demographic, treatment, and disease-related data were captured. Treatment success was defined as clinical response at last follow up. The primary outcome was the development of disease-related complications. Results: Of 185 patients with UP, 60.5% were female, mean age at diagnosis was 41.1 years (±14.2) and median duration of follow up was 4.18 years (IQR 2.0-7.3 years). Most patients ( Conclusion: Despite a short segment of inflammation, UP remains a clinical conundrum as many patients develop refractory disease, disease extension, and complications. Further prospective studies are required to define optimal therapeutic strategies for this under-recognized cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.